MedPath

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

Phase 2
Terminated
Conditions
Pruritus
Burns
Interventions
Drug: Placebo
Drug: Serlopitant
Registration Number
NCT02975271
Lead Sponsor
Vyne Therapeutics Inc.
Brief Summary

Study of the Efficacy, Safety \& Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • Male or female, age 18-65 years at consent.
  • History of serious burn injury
  • Pruritus (itchiness) prior to the initial screening visit and during the screening period
  • Judged to be in good health in the investigator's opinion.

Key

Read More
Exclusion Criteria
  • Prior treatment with study drug or similar drug
  • Pruritus (itchiness) due to another reason besides burn injury/ healing.
  • Presence of any medical condition or disability that, in the investigator's opinion, could interfere with the assessment of safety or efficacy in this trial or compromise the safety of the subject.
  • History of hypersensitivity to study drug or any of its components.
  • Currently pregnant or male partner of pregnant female.
  • Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboMatching dose of Placebo
SerlopitantSerlopitantDose of experimental drug Serlopitant
Primary Outcome Measures
NameTimeMethod
Change in Itch Intensity - Numeric Rating ScaleWeek 6
Secondary Outcome Measures
NameTimeMethod
Itch Intensity Responder Rate - Numeric Rating ScaleWeek 6

Trial Locations

Locations (7)

Study Site 409

🇺🇸

Lincoln, Nebraska, United States

Study Site 403

🇺🇸

Tampa, Florida, United States

Study Site 413

🇺🇸

Seattle, Washington, United States

Study Site 404

🇺🇸

Phoenix, Arizona, United States

Study Site 412

🇺🇸

Gainesville, Florida, United States

Study Site 402

🇺🇸

Washington, District of Columbia, United States

Study Site 401

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath